1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1:

Endovascular treatment and devices used

Case No.Occlusion SitesSpasmolytic AgentsTiming of Drug TherapyMechanical DeviceNo. of Balloon Inflations
1L M2ReoProPostMerci3
Maverick, 2 × 9 mm, Neuroform 2
2L M2/M3 bifurcationReoPro, ActivaseIntra, PostMaverick, 1.5 × 9 mm2
L M2
3L M3ReoProPostMaverick, 2.5 × 15 mm, Wingspan, Enterprise2
L M2/M3 bifurcation
4L M3ReoProPreMaverick, 2.0 × 15 mm4
L M2
L M1
5L M2ReoProPostMerci2
L M1Maverick, 1.5 × 20 mm
6R M3AlteplasePre, IntraMaverick, 1.5 × 9 mm4
R M2
7R M3IV rtPA,a ReoPro, nitroglycerinPostMaverick, 1.5 × 15 mm3
  • a rtPA given in the ED at 2.5 hours after onset of symptoms; patient received endovascular treatment due to persistence of neurologic symptoms.